CELG News 92.26 09/18/2014 04:38:08 Celgene Corp (CELG)
Post# of 273326
Posted On: 09/18/2014 5:38:01 AM
Celgene Corp (CELG) 92.26 $CELG
Final Glance: Biotechnology companies
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Midday Glance: Biotechnology companies
AP - Wed Sep 17, 12:17PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 2.25% Sell Off
Comtex SmarTrend(R) - Mon Sep 15, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.22 to a high of $91.05. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $90.72 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More
at The Street - Mon Sep 15, 11:47AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and he first tackles the upcoming Alibaba IPO.
Nasdaq Underperforms As Leading Growth Stocks Take Heat
at Investor's Business Daily - Mon Sep 15, 10:49AM CDT
The Dow Jones industrial average and S&P 500 held up well Monday, but the Nasdaq took a hit ahead of Tuesday's start of a two-day Federal Reserve meeting. The Nasdaq slumped 1.1%, weighed down by software and solar names. The Dow edged higher, helped...
Stocks Stumble At Open; Mobileye Rebounds
at Investor's Business Daily - Mon Sep 15, 9:26AM CDT
Stocks stumbled in Monday's early going amid some mixed economic reports. The Nasdaq slumped 0.8% to its lowest level since Aug. 22. Biotech, solar and software were among the day's worst groups. The S&P 500 slipped 0.2% and the Dow Jones industrial...
Final Glance: Biotechnology companies
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Midday Glance: Biotechnology companies
AP - Wed Sep 17, 12:17PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.
Look for Shares of Celgene to Potentially Rebound after Yesterday's 2.25% Sell Off
Comtex SmarTrend(R) - Mon Sep 15, 3:51PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $88.22 to a high of $91.05. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $90.72 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders
at Investor's Business Daily - Mon Sep 15, 1:55PM CDT
The Dow Jones industrial average and S&P 500 traded in a tight range Monday, but the Nasdaq took a beating as profit-taking hit several recent highfliers. The Nasdaq moved off lows but still fell 0.9%, hurt by weakness in Tesla Motors (TSLA). Shares...
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More
at The Street - Mon Sep 15, 11:47AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and he first tackles the upcoming Alibaba IPO.
Nasdaq Underperforms As Leading Growth Stocks Take Heat
at Investor's Business Daily - Mon Sep 15, 10:49AM CDT
The Dow Jones industrial average and S&P 500 held up well Monday, but the Nasdaq took a hit ahead of Tuesday's start of a two-day Federal Reserve meeting. The Nasdaq slumped 1.1%, weighed down by software and solar names. The Dow edged higher, helped...
Stocks Stumble At Open; Mobileye Rebounds
at Investor's Business Daily - Mon Sep 15, 9:26AM CDT
Stocks stumbled in Monday's early going amid some mixed economic reports. The Nasdaq slumped 0.8% to its lowest level since Aug. 22. Biotech, solar and software were among the day's worst groups. The S&P 500 slipped 0.2% and the Dow Jones industrial...
(0)
(0)